Benefit-risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma

• Главные авторы: Antonio J García Ruiz (Автор), Nuria García-Agua Soler (Автор), Enrique Herrera Acosta (Автор), Iris Zalaudek (Автор), Josep Malvehy (Автор)
• Формат: ‌
• Опубликовано: BioExcel Publishing Ltd, 2022-07-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background: Sonidegib and vismodegib are Hedgehog pathway inhibitors (HhIs) that play a relevant role in the management of locally advanced basal cell carcinoma (laBCC). This study compared the efficacy and safety of both HhIs based on their available data using effect size measures such as number n...